T Cell – pharmaceutical daily

December 19, 2019 Off

Bristol-Myers Squibb submits BLA for CAR T-Cell therapy lisocabtagene maraleucel (liso-cel) to FDA

Bristol/Myers Squibb said Wednesday it has submitted a Biologics License Applications (BLA) to the FDA, which includes data from Transcend NHL 001 trial, evaluating liso-cel in patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma.

June 21, 2019 Off

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

By BusinessWire

Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.

January 25, 2017 Off

TXCell needs €11M by issuing new shares, covers next year’s requirements

By Dino Mustafić

TxCell has moved into action to raise some money, as it wants to raise gross proceeds of about €11 million by issuing new shares with warrants attached.